Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tharimmune, Inc. - Common Stock (NQ: THAR ) 2.060 -0.090 (-4.19%) Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 144,188 Open 2.180 Bid (Size) 2.020 (10) Ask (Size) 2.190 (1) Prev. Close 2.150 Today's Range 2.000 - 2.180 52wk Range 1.835 - 8.418 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update December 16, 2024 Via ACCESSWIRE Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs December 06, 2024 Via ACCESSWIRE Performance YTD -72.80% -72.80% 1 Month -8.85% -8.85% 3 Month -15.92% -15.92% 6 Month -41.64% -41.64% 1 Year -72.53% -72.53% More News Read More DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 November 27, 2024 Via ACCESSWIRE What's Going On With Tharimmune Shares Monday? November 18, 2024 Via Benzinga THAR Stock Earnings: Tharimmune Reported Results for Q2 2024 August 12, 2024 Via InvestorPlace Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease November 18, 2024 Via ACCESSWIRE Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics November 13, 2024 Via ACCESSWIRE 10 Health Care Stocks Moving In Monday's Pre-Market Session November 04, 2024 Via Benzinga Tharimmune Announces Upcoming Conference Presentations November 04, 2024 Via ACCESSWIRE Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast October 30, 2024 Via Benzinga Exposures Fossil Fuels S&P 500 Edges Lower; US Crude Oil Inventories Fall October 30, 2024 Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities What's Going On With Tharimmune Shares Wednesday? October 30, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session October 30, 2024 Via Benzinga Dow Surges Over 150 Points; Alphabet Posts Upbeat Results October 30, 2024 Via Benzinga Topics Stocks Exposures US Equities Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis October 30, 2024 Via ACCESSWIRE Tharimmune Announces Upcoming Conference Presentations October 25, 2024 Via ACCESSWIRE 12 Health Care Stocks Moving In Friday's After-Market Session October 04, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session September 30, 2024 Via Benzinga Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company September 30, 2024 Via ACCESSWIRE Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab September 16, 2024 Via ACCESSWIRE Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board July 22, 2024 Via ACCESSWIRE Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor July 17, 2024 Via ACCESSWIRE Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104 July 16, 2024 Via ACCESSWIRE Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor July 10, 2024 Via ACCESSWIRE Tharimmune Announces $2.08 Million Private Placement June 20, 2024 Via ACCESSWIRE Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
